Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical pharmacology and therapy

• Publication date

  2002-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1067/mcp.2002.128388PMID 12426511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts

  2004cited by this paper
• The intra- and inter-subject variability of Nifedipine pharmacokinetics in young volunteers

  2004cited by this paper
• Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients.

  2003cited by this paper
• How Important Are Gender Differences in Pharmacokinetics?

  2002cited by this paper
• Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

  2002influential reference
• Gender differences in the disposition of metronidazole.

  2001cited by this paper
• Erythromycin breath test

  2001cited by this paper
• Characterizing the Expression of CYP3A4 and Efflux Transporters (P-gp, MRP1, and MRP2) in CYP3A4-Transfected Caco-2 Cells After Induction with Sodium Butyrate and the Phorbol Ester 12-O-Tetradecanoylphorbol-13-Acetate

  2001influential reference
• Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race

  2001cited by this paper
• Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults

  2001cited by this paper
• The effect of rifampin administration on the disposition of fexofenadine

  2001cited by this paper
• Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• A Comparative Multidose Pharmacokinetic Study of Buspirone Extended‐Release Tablets with a Reference Immediate‐Release Product

  2001cited by this paper
• Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.

  2001cited by this paper
• The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

  2000cited by this paper
• Race and sex influence clearance of nifedipine: Results of a population study

  2000cited by this paper
• Mdr1 limits CYP3A metabolism in vivo.

  2000cited by this paper
• Potential Role of P-Glycoprotein in Affecting Hepatic Metabolism of Drugs

  2000cited by this paper
• Gender‐dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers

  2000cited by this paper
• THE EFFECT OF GENDER ON KETOCONAZOLE INDUCED CHANGES IN TACROLIMUS PHARMACOKINETICS.: Abstract# 192 Poster Board #‐Session: P39‐I

  2000cited by this paper
• Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex‐specific differences after oral administration of verapamil

  2000cited by this paper
• Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.

  2000cited by this paper
• Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.

  2000cited by this paper
• Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans

  2000cited by this paper
• Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)

  1999cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• Open‐Label, Single‐Dose Pharmacokinetic Study of Modafinil Tablets: Influence of Age and Gender in Normal Subjects

  1999cited by this paper
• Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

  1999cited by this paper
• Chronopharmacology of intravenous and oral modified release verapamil.

  1999cited by this paper
• Gender differences in pharmacokinetics and pharmacodynamics.

  1999cited by this paper
• OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

  1999cited by this paper
• Cocaine Pharmacokinetics in Men and in Women During the Follicular and Luteal Phases of the Menstrual Cycle

  1999cited by this paper
• Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A

  1999cited by this paper
• P-Glycoprotein-Dependent Disposition Kinetics of Tacrolimus: Studies in mdr la Knockout Mice

  1999cited by this paper
• Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral.

  1998cited by this paper
• Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam

  1998cited by this paper
• Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.

  1998cited by this paper
• The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

  1998cited by this paper
• Multidrug resistance and its reversal.

  1998cited by this paper
• Assessment of Cytochrome P450 3A4 Activity during the Menstrual Cycle Using Alfentanil as a Noninvasive Probe

  1997cited by this paper
• Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

  1997cited by this paper
• The Role of Cytochrome P450 3A4 in Alfentanil Clearance: Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions

  1997cited by this paper
• Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

  1997cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.

  1996cited by this paper
• A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.

  1996cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• Gender does not affect the degree of induction of tirilazad clearance by phenobarbital

  1996cited by this paper
• Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.

  1996cited by this paper
• Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

  1996cited by this paper
• Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem?

  1996cited by this paper
• Effect of Age and Gender on Pharmacokinetics of Atorvastatin in Humans

  1996cited by this paper
• The erythromycin breath test predicts the clearance of midazolam

  1995cited by this paper
• Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.

  1995cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• Gender related pharmacokinetics of diltiazem in healthy subjects.

  1995cited by this paper
• Gender Effects in Pharmacokinetics and Pharmacodynamics

  1995cited by this paper
• Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms.

  1995influential reference
• Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver.

  1995cited by this paper
• Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects

  1995cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Aging of women alters S‐verapamil pharmacokinetics and pharmacodynamics

  1994cited by this paper
• Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

  1994cited by this paper
• Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers

  1994cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• Effect of age and gender on tirilazad pharmacokinetics in humans

  1994cited by this paper
• Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: Kinetic‐dynamic studies

  1994cited by this paper
• The effects of age and gender on the stereoselective pharmacokinetics of verapamil

  1993cited by this paper
• Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose

  1993cited by this paper
• Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics

  1993cited by this paper
• Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers

  1992cited by this paper
• Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity

  1992cited by this paper
• Effect of age and gender on the activity of human hepatic CYP3A.

  1992cited by this paper
• Influence of Age and Gender on the Plasma Profiles of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitory Activity Following Multiple Doses of Lovastatin and Simvastatin

  1992cited by this paper
• The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease

  1992cited by this paper
• Disposition of alprazolam in human volunteers. Differences between genders.

  1991cited by this paper
• Influence of menstrual cycle and gender on alprazolam pharmacokinetics

  1991cited by this paper
• Influence of Age on the Pharmacokinetics of Alfentanil

  1990cited by this paper
• Effects of age and gender on in vitro properties of human liver microsomal monooxygenases

  1990cited by this paper
• Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

  1990cited by this paper
• Aging and alfentanil disposition in healthy volunteers and surgical patients

  1989cited by this paper
• Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.

  1989cited by this paper
• Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

  1989cited by this paper
• Effects of Age, Gender and Oral Contraceptives on Intramuscular Midazolam Pharmacokinetics

  1988cited by this paper
• Trazodone kinetics: Effect of age, gender, and obesity

  1987influential reference
• DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY

  1986cited by this paper
• Age‐dependent cyclosporine: Pharmacokinetics in marrow transplant recipients

  1986cited by this paper
• Absence of Interaction of Cimetidine and Ranitidine with Intravenous and Oral Midazolam

  1986influential reference
• Lidocaine disposition—Sex differences and effects of cimetidine

  1984cited by this paper
• Effect of Age, Gender, and Obesity on Midazolam Kinetics

  1984influential reference
• Alterations in prednisolone disposition as a result of time of administration, gender and dose.

  1984cited by this paper
• Prednisolone disposition and protein binding in oral contraceptive users.

  1983cited by this paper
• Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.

  1983cited by this paper
• Alprazolam kinetics in the elderly. Relation to antipyrine disposition.

  1983cited by this paper
• Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam.

  1983cited by this paper
• Diazepam kinetics in relation to age and sex.

  1981cited by this paper
• Diazepam disposition determinants

  1980cited by this paper
• Intersubject and dose-related variability after intravenous administration of erythromycin.

  1980cited by this paper

• Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy

  2026cites this paper
• Effect of Testosterone Therapy on Cytochrome P450 3A and P‐Glycoprotein Activities Using Midazolam and Digoxin as Probe Substrates Among Transgender Adults

  2025cites this paper
• Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences

  2025cites this paper
• Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

  2025cites this paper
• The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?

  2025cites this paper
• Systematic Investigation of CYP3A4 Using Side-by-Side Comparisons of Apo, Active Site, and Allosteric-Bound States.

  2025cites this paper
• Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation

  2023cites this paper
• Implications of Sex Differences on the Treatment Effectiveness in Heart Failure with Reduced Ejection Fraction Related to Clinical Endpoints and Quality of Life

  2023cites this paper
• Sex Differences in the Anti-Hypertensive Effect of Calcium-Channel Blockers: A Systematic Review and Meta-Analysis

  2023cites this paper
• Did you forget your cell sex? An update on the inclusion of sex as a variable in AJP-Cell Physiology.

  2023cites this paper
• Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients

  2022cites this paper
• Determination of the frequency of ABCB1 gene polymorphisms (C1236T, C3435T) in the population of the Tashkent region of Uzbekistan

  2022influential citation
• DDDT_A_354270 817..825

  2022cites this paper
• Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension

  2022cites this paper
• Sex differences in the pharmacokinetics and tissue residues of Macleaya cordata extracts in rats

  2022cites this paper
• Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

  2022cites this paper
• Sex Differences in Blood–Brain Barrier Transport of Psychotropic Drugs

  2022cites this paper
• Sedation level with midazolam: A pediatric surgery approach

  2022cites this paper
• Cardiovascular Medications

  2021cites this paper
• Sex-related differences in the pharmacological treatment of heart failure.

  2021cites this paper
• Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours

  2021cites this paper
• Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine

  2021cites this paper
• Beyond Single Nucleotide Polymorphisms: CYP3A5∗3∗6∗7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients

  2020influential citation
• Prophylactic nimodipine treatment improves hearing outcome after vestibular schwannoma surgery in men: a subgroup analysis of a randomized multicenter phase III trial

  2020cites this paper
• Estradiol regulation of P-glycoprotein expression in mouse kidney and human tubular epithelial cells, implication for renal clearance of drugs.

  2019cites this paper
• Individualized medicine: Sex, hormones, genetics, and adverse drug reactions

  2019cites this paper
• Influence of female hormones on the P-glycoprotein functioning

  2018cites this paper
• Gender differences in the effects of cardiovascular drugs

  2017cites this paper
• Sex differences in transplantation.

  2017cites this paper
• Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees

  2017cites this paper
• BAŞARISIZ TEDAVİNİN OLASI SORUMLUSU: P GLİKOPROTEİNLER Reason for the Ineffective Treatment: P Glycoproteins

  2017cites this paper
• All Cells Have a Sex: Studies of Sex Chromosome Function at the Cellular Level

  2017cites this paper
• Pharmacokinetic Investigation of Quetiapine Transport across Blood-Brain Barrier Mediated by Lipid Core Nanocapsules Using Brain Microdialysis in Rats.

  2016cites this paper
• Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.

  2016cites this paper
• Sex differences in excipient effects: Enhancement in ranitidine bioavailability in the presence of polyethylene glycol in male, but not female, rats.

  2016cites this paper
• BDDCS, the Rule of 5 and drugability.

  2016cites this paper
• No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans.

  2016cites this paper
• Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine

  2016cites this paper
• Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes

  2015cites this paper
• Sex Differences in Metabolism and Pharmacokinetics

  2015cites this paper
• Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism

  2014cites this paper
• The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

  2014cites this paper
• Single-Dose Pharmacokinetics of the Renin Inhibitor ACT-077825 in Elderly and Young Subjects of Both Sexes

  2014cites this paper
• ADVERSE EVENT REPORTING FOR A FOOD EFFECT BIOAVAILABILITY STUDY OF ROXITHROMYCIN

  2014cites this paper
• Modulation of cardiac cytochrome P450 in patients with heart failure

  2014cites this paper
• Estudios de factores genéticos y ambientales que regulan el metabolismo de ebastina en voluntarios sanos

  2013cites this paper
• Interrelationship between Heliobacter pylori and P-glycoprotein: potential role in drug resistance and carcinogenicity

  2013cites this paper
• Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice.

  2013cites this paper
• Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients

  2013cites this paper
• Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

  2013influential citation
• Perspectives on a pharmacokinetics legend: C versus T (contributions over time).

  2013cites this paper
• ABC taşıyıcı proteinleri: Sirkadiyan ritimler ve cinsiyete bağlı farklılıklar

  2013cites this paper
• Hormonal regulation of hepatic drug biotransformation and transport systems.

  2013cites this paper
• Clobazam Therapeutic Drug Monitoring: A Comprehensive Review of the Literature With Proposals to Improve Future Studies

  2013cites this paper
• Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs

  2012cites this paper
• Serum Potassium Predicts Time to Blood Pressure Response Among African-Americans with Hypertensive Nephrosclerosis

  2012cites this paper
• Sex and gender differences in cardiovascular drug therapy.

  2012cites this paper
• Prediction of Cytochrome P450-Mediated Hepatic Drug Clearance in Neonates, Infants and Children

  2012cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment

  2012cites this paper
• Effect of Quercetin on CYP3A Activity in Chinese Healthy Participants

  2012cites this paper
• Gender and pharmacokinetics

  2012cites this paper
• Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

  2012cites this paper
• Analysis of Gender Differences in Physician’s Desk Reference

  2011cites this paper
• In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.

  2011cites this paper
• "In-vivo" phenotyping of CYP3A using midazolam as probe drug : development of novel approaches based on highly sensitive LC-MS/MS methods

  2011cites this paper
• Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.

  2011cites this paper
• Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors.

  2011cites this paper
• General Principles of Pharmacokinetics and Pharmacodynamics

  2011cites this paper
• Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy

  2011cites this paper
• [Interaction between azole antifugals drugs and tacrolimus in four kidney transplant patients].

  2011cites this paper
• Gender‐related differences on P‐glycoprotein‐mediated drug intestinal transport in rats

  2011cites this paper
• Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy

  2010cites this paper
• Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End‐Stage Renal Disease

  2010cites this paper
• Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient

  2010cites this paper
• Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir

  2010cites this paper
• Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

  2010cites this paper
• Impact of age, sex, and comorbidity on cancer therapy and disease progression.

  2010cites this paper
• Review of Gender Differences in Medicine and Primary Factors Resulting in Gender Differences

  2010cites this paper
• Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice

  2009influential citation
• Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies

  2009cites this paper
• CYP3A4 and CYP3A5 Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease

  2009cites this paper
• The role of P-glycoprotein in the pharmacokinetics and tissue distribution of a hepatitis C virus protease inhibitor.

  2009cites this paper
• Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid

  2009cites this paper
• Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

  2009cites this paper
• Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances.

  2009cites this paper
• Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome.

  2009influential citation
• Patient Sex and its Influence on General Anaesthesia

  2009cites this paper
• Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.

  2009cites this paper
• Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.

  2009cites this paper
• Sex Differences of Drug-metabolizing Enzyme: Female Predominant Expression of Human and Mouse Cytochrome P450 3A Isoforms

  2009cites this paper
• Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs

  2008cites this paper
• Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice

  2008cites this paper
• [Combination therapy of atherogenic dyslipidemias in women].

  2008cites this paper
• Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

  2008cites this paper
• Implications of gender and pregnancy for antiretroviral drug dosing

  2008cites this paper
• Sex-specific differences in CYP450 isoforms in humans

  2008influential citation
• Gender differences in pharmacological response.

  2008cites this paper
• In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4

  2007cites this paper
• Human intestinal P‐glycoprotein activity estimated by the model substrate digoxin

  2007cites this paper
• Pharmacological Differences between Men and Women

  2007cites this paper